Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 271-278

  Brave, Sandra R ^a   Odedra, Rajesh ^a   James, Neil H ^a   Smith, Neil R ^a   Marshall, Gayle B ^a   Acheson, Kerry L ^a   Baker, Dawn ^a   Howard, Zoe ^a   Jackson, Lynsay ^a   Ratcliffe, Kirsty ^a   Wainwright, Anna ^a   Lovick, Susan C ^a   Hickinson, D Mark ^a   Wilkinson, Robert W ^a   Barry, Simon T ^a   Speake, Georgina ^a   Ryan, Anderson J ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

EGFR; Endothelial cells; Lung cancer; Vandetanib; VEGFR 2; Xenografts

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASMS; PHENOTYPE; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956051199     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1022     Document Type: Article

References (28)

1. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002.
2. Ryan AJ and Wedge SR: ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92 (Suppl. 1): S6-S13, 2005. (Pubitemid 40897411)
3. Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002. (Pubitemid 35204731)
4. Heymach JV, Johnson BE, Prager D, et al: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25: 4270-4277, 2007. (Pubitemid 47548567)
5. Natale RB, Bodkin D, Govindan R, et al: Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol 27: 2523-2529, 2009.
6. Heymach JV, Paz-Ares L, De Braud F, et al: Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26: 5407-5415, 2008.
7. Morabito A, Piccirillo MC, Falasconi F, et al: Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14: 378-390, 2009.
8. Kiura K, Nakagawa K, Shinkai T, et al: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3: 386-393, 2008. (Pubitemid 351489479)
9. Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174, 2008.
10. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338, 2009.
11. Annunziata CM, Walker AJ, Minasian L, et al: Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 16: 664-672, 2010.
12. Baselga J, Trigc JM, Rojo F, et al: Pharmacodynamic assessment of ZD6474 (ZACTIMA (TM)) in the skin of patients with previously treated metastatic breast cancer. Clin Cancer Res 11: S9027-S9027, 2005.
13. Barker AJ, Gibson KH, Grundy W, et al: Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11: 1911-1914, 2001.
14. Hennequin LF, Stokes ES, Thomas AP, et al: Novel 4-anilino-quinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45: 1300-1312, 2002. (Pubitemid 34263566)
15. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-4400, 2005. (Pubitemid 40775678)
16. Smith NR, Baker D, James NH, et al: Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 16: 3548-3561, 2010.
17. Smith NR, James NH, Oakley I, et al: Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6: 2198-2208, 2007. (Pubitemid 47294748)
18. Guo M, Liu S, Herman JG, Zhuang H and Lu F: Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol Ther 5: 152-155, 2006. (Pubitemid 43327533)
19. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N and Nishio K: Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474 Cancer Res 64: 9101-9104, 2004.
20. Yeh JJ, Routh ED, Rubinas T, et al: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8: 834-843, 2009.
21. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
22. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005. (Pubitemid 41058344)
23. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006. (Pubitemid 44917502)
24. Herbst RS, Sun Y, Eberhardt WE, et al: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619-626, 2010.
25. Naumov GN, Nilsson MB, Cascone T, et al: Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15: 3484-3494, 2009.
26. Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N and Nishio K: Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (Iressa)-sensitive and resistant xenograft models. Cancer Sci 95: 984-989, 2004. (Pubitemid 40089591)
27. Ichihara E, Ohashi K, Takigawa N, et al: Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res 69: 5091-5098, 2009.
28. Conrad C, Ischenko I, Kohl G, et al: Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 18: 569-579, 2007. (Pubitemid 46597412)